Biodexa Enters Into Exclusive License to eRapaâ„¢, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP) Worldwide rights come with $17 million in non-dilutive grant funding ...
Some results have been hidden because they may be inaccessible to you